

CRITICAL THERAPEUTICS INC

Form 4/A

October 21, 2005

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Warren Howland Shaw

2. Issuer Name **and** Ticker or Trading  
Symbol  
CRITICAL THERAPEUTICS INC  
[CRTX]

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
(Month/Day/Year)  
10/11/2005

☒ Director ☐ 10% Owner  
☐ Officer (give title below) ☐ Other (specify below)

C/O CRITICAL THERAPEUTICS,  
INC., 60 WESTVIEW STREET

(Street)

4. If Amendment, Date Original  
Filed(Month/Day/Year)  
10/11/2005

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

LEXINGTON, MA 02421

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D) Price			
Common Stock	10/11/2005		S <sup>(1)</sup>		2,100	D \$ 8.49	305,144	D	
Common Stock	10/11/2005		S <sup>(1)</sup>		1,500	D \$ 8.49	303,644	D	
Common Stock	10/11/2005		S <sup>(1)</sup>		1,200	D \$ 8.49	302,444	D	
Common Stock	10/11/2005		S <sup>(1)</sup>		1,100	D \$ 8.5	301,344	D	
Common Stock	10/11/2005		S <sup>(1)</sup>		500	D \$ 8.57	300,844	D	

# Edgar Filing: CRITICAL THERAPEUTICS INC - Form 4/A

Common Stock	10/11/2005	S <sup>(1)</sup>	500	D	\$ 8.54	300,344	D
Common Stock	10/11/2005	S <sup>(1)</sup>	400	D	\$ 8.5	299,944	D
Common Stock	10/11/2005	S <sup>(1)</sup>	400	D	\$ 8.48	299,544	D
Common Stock	10/11/2005	S <sup>(1)</sup>	300	D	\$ 8.51	299,244	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 6)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

### Reporting Owner Name / Address

### Relationships

Director 10% Owner Officer Other

Warren Howland Shaw  
C/O CRITICAL THERAPEUTICS, INC.  
60 WESTVIEW STREET  
LEXINGTON, MA 02421

X

## Signatures

/s/ Scott B. Townsend,  
Attorney-in-Fact

10/21/2005

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2005.

### Remarks:

This amendment is being filed to correct the number of non-derivative securities beneficially owned after the reported transaction.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.